AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19330248 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass graft
Number of subjects: 20
Study 19330248 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass graft
Number of subjects: 20
Study 19331677 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical distress (3rd tertile)
Number of subjects: 433
Study 19331677 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (3rd tertile)
Number of subjects: 433
Study 19331677 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical distress (in multivariate analysis)
Number of subjects: 433
Study 19331677 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (in multivariate analysis)
Number of subjects: 433
Study 19332630 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN; Enbrel)
Number of subjects: 14000
Study 19332768 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide plus dexamethasone
Number of subjects: 130
Study 19333404 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0
Study 19333404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19335386 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 240
Study 19335386 — intervention group
Group type: COMPARATOR
Intervention: IR-MPH
Number of subjects: 240
Study 19336634 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19336742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.5 mg/m² on days 1, 4, 8, and 11, every 21 days)
Number of subjects: 16
Study 19336742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 16
Study 19339093 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 treatments/week (daily trial)
Number of subjects: 100
Study 19339093 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 nocturnal treatments/week (nocturnal trial)
Number of subjects: 100
Study 19339093 — intervention group
Group type: COMPARATOR
Intervention: 3 treatments/week (control for daily trial)
Number of subjects: 100
Study 19339093 — intervention group
Group type: COMPARATOR
Intervention: 3 conventional treatments/week (control for nocturnal trial)
Number of subjects: 100
Study 19339913 — intervention group
Group type: EXPERIMENTAL
Intervention: MTRR 66A>G genotype (MTRR 66AA, AG, GG)
Number of subjects: 140
Study 19339913 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MTRR 66AA, AG, GG)
Number of subjects: 140
Study 19339913 — intervention group
Group type: COMPARATOR
Intervention: Control group (wild-type patients)
Number of subjects: 140
Study 19341509 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram up to 60 mg/d for up to 14 weeks
Number of subjects: 2876
Study 19344074 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with corticotropinomas
Number of subjects: 20
Study 19344074 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents)
Number of subjects: 20
Study 19344390 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) levels in patients with SCD
Number of subjects: 177
Study 19344390 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine to ADMA ratio in patients with homozygous SCD
Number of subjects: 177
Study 19344390 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ADMA with clinical variables
Number of subjects: 177
Study 19344390 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ADMA with pulmonary hypertension (PH)
Number of subjects: 177
Study 19344390 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels and early mortality
Number of subjects: 177
Study 19345439 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 680
Study 19348029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily for 4 weeks, with possible escalation to 8 mg based on efficacy and tolerability assessment.
Number of subjects: 516
Study 19348029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine treatment satisfaction at week 12.
Number of subjects: 516
Study 19348029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Perception of Bladder Condition (PPBC) at week 12.
Number of subjects: 516
Study 19348029 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-q Symptom Bother and Health-Related Quality of Life (HRQL) scales at week 12.
Number of subjects: 516
Study 19348685 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (new long-acting anticoagulant drug)
Number of subjects: 0
Study 19348685 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 0
Study 19350213 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring (CGMS) with norepinephrine therapy
Number of subjects: 50
Study 19350213 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous continuous glucose monitoring (CGMS) without norepinephrine therapy
Number of subjects: 50
Study 19350213 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring (CGMS)
Number of subjects: 50
Study 19353673 — intervention group
Group type: EXPERIMENTAL
Intervention: Image domain TGRAPPA reconstruction
Number of subjects: 0
Study 19357147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 40
Study 19357147 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study 19358725 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily
Number of subjects: 279
Study 19358725 — intervention group
Group type: COMPARATOR
Intervention: atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily
Number of subjects: 279
Study 19360102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives
Number of subjects: 103
Study 19360102 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 103
Study 19360102 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use prior to screening
Number of subjects: 103
Study 19360102 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles to contraceptive use
Number of subjects: 103
Study 19360102 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall contraceptive use
Number of subjects: 103
Study 19364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-daclizumab combination therapy (months 0-5.5)
Number of subjects: 15
Study 19364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab monotherapy (months 6.5-15.5)
Number of subjects: 15
Study 19364933 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta monotherapy
Number of subjects: 15
Study 19364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg) as an intravenous infusion every 4 weeks
Number of subjects: 15
Study 19364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot biomarkers (increase in CD56bright natural killer cells and decrease in CD8+ T cells)
Number of subjects: 15
Study 19364977 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP categories (<120, 120 to 129, 130 to 139, 140 to 159, and >=160 mm Hg)
Number of subjects: 34221
Study 19364977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP categories (<65, 65 to 74, 75 to 84, 85 to 89, 90 to 94, and >=95 mm Hg)
Number of subjects: 34221
Study 19364977 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP categories (updated models)
Number of subjects: 34221
Study 19364977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP categories (updated models)
Number of subjects: 34221
Study 19365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab, 1.0% for 3 weeks
Number of subjects: 10
Study 19365014 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-electrode epiretinal prosthesis
Number of subjects: 1
Study 19365014 — intervention group
Group type: COMPARATOR
Intervention: System off (control)
Number of subjects: 1
Study 19366446 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate treatment with tumor-specific frequencies
Number of subjects: 163
Study 19366777 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 23
Study 19366777 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative HSCT
Number of subjects: 23
Study 19366777 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 23
Study 19369238 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering light stimulation
Number of subjects: 40
Study 19369238 — intervention group
Group type: COMPARATOR
Intervention: Sublingual application of 0.8 mg GTN
Number of subjects: 40
Study 19369372 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden Rice (65-98 g servings containing 0.99-1.53 mg beta-carotene) with 10 g butter
Number of subjects: 5
Study 19369372 — intervention group
Group type: COMPARATOR
Intervention: [13C10]retinyl acetate reference dose (0.4-1.0 mg) in oil
Number of subjects: 5
Study 19369372 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden Rice beta-carotene
Number of subjects: 5
Study 19371392 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib 1.3 mg/m² (i.v. bolus days 1, 4, 8, 11) for up to eight 21-day cycles (C)
Number of subjects: 111
Study 19375217 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally for 1 week, 1 month, or until disease progression.
Number of subjects: 12
Study 19375217 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally.
Number of subjects: 12
Study 19376309 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus SVR
Number of subjects: 1000
Study 19376309 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 1000
Study 19376495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg) administered as 3 consecutive monthly injections, followed by a variable-dosing regimen based on OCT criteria.
Number of subjects: 40
Study 19376616 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable hemodialysis device for 4 to 8 hours
Number of subjects: 8
Study 19377166 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 75
Study 19377166 — intervention group
Group type: COMPARATOR
Intervention: non-VR group
Number of subjects: 75
Study 19377166 — intervention group
Group type: COMPARATOR
Intervention: waiting list (WL) group
Number of subjects: 75
Study 19377385 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy of OAC, aspirin and clopidogrel
Number of subjects: 0
Study 19377385 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 19380364 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted resection of indicated tumors
Number of subjects: 36
Study 19380866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus chemotherapy
Number of subjects: 0
Study 19380866 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 0
Study 19380866 — intervention group
Group type: COMPARATOR
Intervention: Upfront chemotherapy
Number of subjects: 0
Study 19381280 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave UMI identified by DE-CMR
Number of subjects: 185
Study 19381280 — intervention group
Group type: COMPARATOR
Intervention: Q-wave UMI identified by electrocardiography
Number of subjects: 185
Study 19381280 — intervention group
Group type: COMPARATOR
Intervention: Patients without MI
Number of subjects: 185
Study 19381280 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave UMI patients
Number of subjects: 185
Study 19381280 — intervention group
Group type: COMPARATOR
Intervention: Q-wave UMI patients
Number of subjects: 185
Study 19381280 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave UMI
Number of subjects: 185
Study 19383032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg b.i.d.)
Number of subjects: 598
Study 19383032 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (8 mg q.d.)
Number of subjects: 598
Study 19383032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 598
Study 19383032 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 598
Study 19386738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron excretion in men
Number of subjects: 53
Study 19386738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron excretion in menstruating women
Number of subjects: 53
Study 19386738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron excretion in postmenopausal women
Number of subjects: 53
Study 19386738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron excretion in menstruating women (excluding hormonal contraceptive users)
Number of subjects: 53
Study 19386738 — intervention group
Group type: EXPERIMENTAL
Intervention: Body iron change in menstruating women
Number of subjects: 53
Study 19386738 — intervention group
Group type: EXPERIMENTAL
Intervention: Body iron change in men
Number of subjects: 53
Study 19386746 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured metabolizable energy intake (MEI)
Number of subjects: 34
Study 19386746 — intervention group
Group type: COMPARATOR
Intervention: Food records
Number of subjects: 34
Study 19386937 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19387077 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXAA (3000 mg x m(-2))
Number of subjects: 21
Study 19387077 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXAA (IV infusion for 20 minutes)
Number of subjects: 21
Study 19387077 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXAA (IV infusion for 6 weeks, one dose per week)
Number of subjects: 21
Study 19387077 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXAA (various doses)
Number of subjects: 21
Study 19387313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient neurocognitive testing
Number of subjects: 116
Study 19387313 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial in-hospital testing
Number of subjects: 116
Study 19388836 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI >or= 40.0 kg/m(2))
Number of subjects: 2037
Study 19389332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium administration for 4 weeks
Number of subjects: 28
Study 19394037 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose extended-release methylphenidate (OROS MPH) up to 1.5 mg/kg/d
Number of subjects: 114
Study 19394037 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose extended-release methylphenidate (OROS MPH)
Number of subjects: 114
Study 19394543 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair of TAAA using custom designed multi-branched stent-grafts
Number of subjects: 38
Study 19394543 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair of TAAA
Number of subjects: 38
Study 19394894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg once daily
Number of subjects: 126
Study 19395440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting direct LDL-C
Number of subjects: 27331
Study 19395440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Friedewald LDL-C
Number of subjects: 27331
Study 19395440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting direct LDL-C
Number of subjects: 27331
Study 19395440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting LDL-C measurements
Number of subjects: 27331
Study 19398716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride (TLK199 tablets) at dose levels of 200 to 6000 mg/day
Number of subjects: 45
Study 19398716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride (TLK199 tablets)
Number of subjects: 45
Study 19399156 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT-aided malaria diagnosis
Number of subjects: 1887
Study 19399156 — intervention group
Group type: COMPARATOR
Intervention: Symptom-based clinical diagnosis (CD) alone
Number of subjects: 1887
Study 19399550 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative oral feeding (liquid diet on POD 2, soft diet on POD 3)
Number of subjects: 66
Study 19399550 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet schedule (control group)
Number of subjects: 66
Study 19399946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP, PetCO2, and clinical assessment
Number of subjects: 441
Study 19399946 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP alone
Number of subjects: 441
Study 19399946 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP in combination with clinical assessment
Number of subjects: 441
Study 19399946 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP > or = 2000 pg/mL and PetCO2 < or = 4 kPa
Number of subjects: 441
Study 19399946 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of COPD/asthma in acute HF dyspneic patients
Number of subjects: 441
Study 19399946 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of HF in COPD/asthma dyspneic patients
Number of subjects: 441
Study 19400961 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone support for smoking cessation
Number of subjects: 2576
Study 19400961 — intervention group
Group type: COMPARATOR
Intervention: Reactive telephone support for smoking cessation
Number of subjects: 2576
Study 19400961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) offered in addition to telephone counselling
Number of subjects: 2576
Study 19400961 — intervention group
Group type: COMPARATOR
Intervention: No offer of Nicotine Replacement Therapy (NRT)
Number of subjects: 2576
Study 19402886 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) at a dosage of 0.625 mg/d for 1 year
Number of subjects: 100
Study 19402886 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 100
Study 19403641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (3.5 g x kg FFM(-1) x d(-1), +35% energy intake)
Number of subjects: 24
Study 19403641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 24
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine treatment
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dosage of prednisone (0.15-0.4 mg/kg/day)
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lipoprotein(a) level
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased creatinine clearance
Number of subjects: 221
Study 19404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 221
Study 19406289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower thoracic spinal cord stimulation (SCS)
Number of subjects: 9
Study 19406289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation of any 2 leads of SCS
Number of subjects: 9
Study 19406290 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) performed at home by subjects or caregivers
Number of subjects: 9
Study 19406290 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 9
Study 19406978 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous LL patients
Number of subjects: 260
Study 19407319 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 66
Study 19407319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 19407658 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pill amlodipine/atorvastatin (5/10-10/80 mg) with lifestyle modification
Number of subjects: 2245
Study 19407658 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pill amlodipine/atorvastatin
Number of subjects: 2245
Study 19411292 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 34
Study 19411292 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 34
Study 19411368 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression group
Number of subjects: 30
Study 19411368 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison group
Number of subjects: 30
Study 19411393 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 81
Study 19411393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially) then switched to Etanercept
Number of subjects: 81
Study 19411393 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 81
Study 19412327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile diary
Number of subjects: 12
Study 19412327 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 12
Study 19415121 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized therapy based on BRCA1 mRNA levels
Number of subjects: 123
Study 19415121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with low BRCA1
Number of subjects: 123
Study 19415121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with intermediate BRCA1
Number of subjects: 123
Study 19415121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with high BRCA1
Number of subjects: 123
Study 19415121 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low BRCA1 and low RAP80
Number of subjects: 123
Study 19415121 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP80 expression
Number of subjects: 123
Study 19416525 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Tailored (ST) packet
Number of subjects: 0